Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Pasireotide
A broader-spectrum somatostatin analogue approved for specific endocrine disorders including Cushing's disease.
Octreotide
The foundational somatostatin analogue, used for acromegaly and symptom control in certain neuroendocrine tumours.
How far human research has progressed
Pasireotide
Approved in defined endocrine indicationsOctreotide
Long-approved medicine, multiple formulationsClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Pasireotide
Not separately assessed; see the full profile.Octreotide
Not separately assessed; see the full profile.Human research context
Pasireotide
Approved in defined endocrine indicationsOctreotide
Long-approved medicine, multiple formulationsHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Pasireotide
Octreotide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Pasireotide
Octreotide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Pasireotide
Octreotide
Regulatory status (legal position, not proof it works)
Pasireotide
Named regulators: FDA (US)
FDA-approved in specific endocrine disorders: Signifor for Cushing's disease, and Signifor LAR for acromegaly (with formulation-specific labelling). Approvals are indication- and formulation-specific.
Octreotide
Named regulators: FDA (US)
FDA-approved for acromegaly and for symptom control associated with certain neuroendocrine tumours (e.g. carcinoid and VIP-secreting tumours), depending on product and label. Approvals are indication-specific.
Common claims
Pasireotide
- · Reduces cortisol production in Cushing's disease
- · Controls growth hormone in acromegaly
Octreotide
- · Controls growth-hormone excess in acromegaly
- · Controls hormone-driven symptoms of certain neuroendocrine tumours
How settled our evidence rating is
Pasireotide
Octreotide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Pasireotide
No established human cancer signal; used to treat hormone-secreting pituitary disease.Octreotide
Used to control symptoms of hormone-secreting neuroendocrine tumours — a therapeutic oncology context, not a cancer-risk signal.What this adds up to, in plain English
Pasireotide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Octreotide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation